Skip to content
10-K

Annual Report

Actinium Pharmaceuticals, Inc. ATNM

0001213900-24-028038

← back to feed
Filed
Mar 29, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Mar 27, 2024 29.4M sh
Shares Diluted FY 2023 · Dec 31, 2022 24.14M sh
Capex FY 2023 · Dec 31, 2022 $366K
Operating Cash Flow FY 2023 · Dec 31, 2022 $8.64M
Cash And Equivalents FY 2023 · Dec 31, 2022 $108.91M
Current Liabilities FY 2023 · Dec 31, 2022 $10.63M
Total Liabilities FY 2023 · Dec 31, 2022 $47.71M
Current Assets FY 2023 · Dec 31, 2022 $110.94M
Total Assets FY 2023 · Dec 31, 2022 $114.19M
Eps Diluted FY 2023 · Dec 31, 2022 −$1.37
Eps Basic FY 2023 · Dec 31, 2022 −$1.37
Sga Expense FY 2023 · Dec 31, 2022 $12M
Rd Expense FY 2023 · Dec 31, 2022 $23.14M
Net Income FY 2023 · Dec 31, 2022 −$33.02M
Operating Income FY 2023 · Dec 31, 2022 −$34.1M
Revenue FY 2023 · Dec 31, 2022 $1.03M
Stockholders Equity FY 2023 · Dec 31, 2021 $73.55M